Last updated 2026-06-18
- Acquired by Purple Biotech, Jan 2017
Total raised
—
Stage
Acquired
Founded
2013
Headcount
6
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
TyrNovo is developing a cancer treatment that eliminates a key protein, an approach that has the potential to improve cancer therapy, prevent drug resistance, and increase life expectancy. The companys novel approach promotes the degradation of insulin-receptor substrates 1 and 2. While targeted anticancer drugs inhibit the on signal, TyrNovos compounds activate the off switch, extensively blocking major oncogenic pathways. The compounds NT157 and NT219 have been licensed exclusively by TyrNovo from Yissum Research Development Company of the Hebrew University of Jerusalem. TyrNovos activity has been entirely integrated into Kitov Pharmaceuticals.
Q&A
- What is TyrNovo's primary focus?
- TyrNovo specializes in developing targeted therapies to prevent resistance to cancer drugs, aiming to improve cancer treatment and increase life expectancy.
- What is TyrNovo's core technological approach?
- TyrNovo's novel approach promotes the degradation of insulin-receptor substrates 1 and 2, activating the off switch to extensively block major oncogenic pathways in cancer treatment.
- Which compounds has TyrNovo licensed?
- TyrNovo has exclusively licensed compounds NT157 and NT219 from Yissum Research Development Company of the Hebrew University of Jerusalem.
- When was TyrNovo founded?
- TyrNovo was founded in September 2013.
- What is TyrNovo's current status?
- TyrNovo was acquired by Purple Biotech in January 2017 and is currently inactive.
- What is TyrNovo's primary sector classification?
- TyrNovo's primary sector is Health Tech & Life Sciences, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Does TyrNovo hold any patents?
- Yes, TyrNovo holds one patent.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
cancerpersonalizationbiopharmaceuticaldrug-discoveryoncologypharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2013-9 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Acquired (Inactive) by Purple Biotech on Jan 2017 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Purple Biotech 2017-01
Radar intelligence
Patents
| EPO | 3 |
|---|
Publications (Crossref)
| Works | 7 |
|---|